Minimed Group, INC

MiniMed Group, Inc. announced a robust start to fiscal year 2027, with net sales reaching $843 million, a 17% increase driven by accelerated U.S. growth and strong international performance.

MiniMed Group, Inc. reports the resignation of its Senior Vice President, General Counsel, and Corporate Secretary, Courtney Nelson Wills, effective September 25, 2026.

MiniMed Group, Inc. announced an expansion of its Board of Directors with two new appointments and set the date and record date for its 2026 Annual Meeting of Stockholders.

MiniMed announced record fiscal year 2026 net sales exceeding $3 billion, with Q4 sales up 15.6% year-over-year, driven by international markets and new product clearances.

MiniMed Group, Inc. reports the resignation of director Brett Wall and the appointment of Scott Cundy to the Board of Directors.

MiniMed Group, Inc. disclosed that its parent company, Medtronic plc, experienced a cybersecurity incident involving unauthorized access to IT systems, with no expected material impact on MiniMed's business or financial results.

MiniMed Group, Inc. announced a 16.6% increase in net sales for the first quarter of fiscal year 2027, driven by robust performance in CGM and pump segments, alongside strategic product advancements.

MiniMed Group reports Q3 2026 net sales of $790 million, reflecting a 15% increase, alongside a net loss of $111 million driven by restructuring and litigation charges.

MiniMed Group, Inc. announced its fiscal year 2026 results, showcasing a 14% increase in net sales to $3.1 billion, primarily fueled by robust international growth in its CGM segment.

MiniMed outlines its strategy for accelerated growth and market leadership in automated insulin delivery following its separation from Medtronic, highlighting product innovation and strong financial performance.

Mini-Med has filed a 425 document detailing a strategic split-off transaction aimed at separating its diabetes business into a new, independent entity.

Medtronic plc has initiated an exchange offer to spin off its remaining equity interest in MiniMed, filing a Form S-4 registration statement with the SEC.

MiniMed announces the launch of an exchange offer, marking the final step in its separation from Medtronic and transition to a fully independent public company.

MiniMed announces the final major step in its separation from Medtronic, launching an exchange offer for its remaining equity interest to operate as a fully independent company.

Medtronic plc announced an exchange offer allowing shareholders to swap Medtronic shares for MiniMed common stock as part of its separation strategy.

MiniMed Group, Inc. has announced its 2026 Annual Meeting of Stockholders, detailing key proposals including director elections, auditor ratification, and executive compensation votes.

MiniMed Group, a global leader in diabetes technology, filed an S-1/A for its initial public offering of 28 million shares, showcasing robust revenue growth and product innovation despite reporting significant net losses and operational challenges.

MiniMed Group, Inc., a global medical technology company specializing in diabetes management, filed an amended S-1 registration statement detailing its initial public offering of 28 million shares and its spin-off from Medtronic, aiming to accelerate growth as an independent entity.

Medtronic plc has filed a Schedule 13G reporting beneficial ownership of 90% of the outstanding common stock of MiniMed Group, Inc.